戻る Agenda
Session 3: Biotherapeutic Products and Biosimilars
Session Chair(s)
Susanne Ausborn, PhD
Global Head International Regulatory Policy
Roche, Switzerland
Myriam Sedrati
Regulatory Affairs Director North and West Africa
Merck Sharp & Dohme, Morocco
• Updates from the Region: o Morocco o Algeria o Tunisia • Vaccines Registrations • Biotherapeutic products: Clinical aspects to be addressed
Speaker(s)
![Hye-Na Kang, DVM](/_Images/member/Generic_Image_Missing-Profile.jpg)
WHO Guidelines
Hye-Na Kang, DVM
Access To Medicines and Health Products, World Health Organization, Switzerland
Scientist
![Kawaldip Sehmi](/_Images/member/Generic_Image_Missing-Profile.jpg)
Patients’ Perspective on Biosimilars
Kawaldip Sehmi
International Alliance Of Patients' Organizations (IAPO), United Kingdom
CEO
Interchangeability and Extrapolation
Virginia Acha, PhD, MSc
Merck Sharpe & Dohme LLC , United States
AVP, Global Regulatory Policy
• Updates from the Region: Tunisia
Houda Ben Khedija
Ministère de la santé publique, Tunisia
Directeur de l’Inspection Pharmaceutique
Peter J. Pitts
Center for Medicine in the Public Interest (CMPI), United States
President